PASCAL GAUDREAULT: Open Payments
NPI 1811982754 · FESTUS, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,296 in 72 payments from 21 companies in 2025. Trend: 2023 $1,267 · 2024 $1,833 · 2025 $1,296
Food & beverage: $1,296
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $267 |
| AstraZeneca Pharmaceuticals LP | 9 | $189 |
| Novo Nordisk Inc | 11 | $152 |
| PFIZER INC. | 10 | $136 |
| Sumitomo Pharma America, Inc. | 3 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| Lilly USA, LLC | 2 | $46 |
| Exact Sciences Corporation | 2 | $41 |
| Medtronic, Inc. | 2 | $40 |
| Amgen Inc. | 2 | $37 |
Products named: VRAYLAR, BREZTRI, GEMTESA, UBRELVY, NURTEC ODT, CAPLYTA, Ozempic, AIRSUPRA.
Industry payments across MO — which companies pay providers there.
